UK markets open in 55 minutes
  • NIKKEI 225

    26,129.87
    +194.25 (+0.75%)
     
  • HANG SENG

    21,816.08
    -43.71 (-0.20%)
     
  • CRUDE OIL

    108.76
    +0.33 (+0.30%)
     
  • GOLD FUTURES

    1,812.50
    +11.00 (+0.61%)
     
  • DOW

    31,097.26
    +321.86 (+1.05%)
     
  • BTC-GBP

    15,804.03
    -9.26 (-0.06%)
     
  • CMC Crypto 200

    413.13
    -7.01 (-1.67%)
     
  • ^IXIC

    11,127.84
    +99.14 (+0.90%)
     
  • ^FTAS

    3,940.03
    -0.87 (-0.02%)
     

Bayer wins fourth Roundup weedkiller case in U.S

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FRANKFURT (Reuters) - A U.S. jury found Bayer's Roundup weedkiller did not cause an Oregon man's cancer, the German agriculture and pharmaceuticals company said on Saturday, handing the firm its fourth consecutive trial victory over such claims.

The verdict, reached on Friday by the Circuit Court of Jackson County, Oregon, is "consistent with the assessments of expert regulators worldwide as well as the overwhelming evidence from four decades of scientific studies concluding that Roundup can be used safely and is not carcinogenic", Bayer said.

"We continue to stand behind the safety of Roundup and will confidently defend the safety of our product as well as our good faith actions in any future litigation."

Glyphosate is the active ingredient in Bayer brands such as Roundup and RangerPro. It has been at the centre of mass litigation in the United States brought mostly by residential gardeners claiming the weedkiller caused their cancer.

The company has spent billions of dollars to settle close to 100,000 Roundup cases.

(Reporting by Christoph Steitz; Editing by Mark Potter)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting